Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Pexastimogene devacirepvec by Sillajen Biotherapeutics for Prostate Cancer: Likelihood of Approval
Pexastimogene devacirepvec is under clinical development by Sillajen Biotherapeutics and currently in Phase II for Prostate Cancer. According to GlobalData,...